WuXi XDC and TOT BIOPHARM Delay Dispatch of Composite Offer Document for Voluntary Cash Takeover

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an announcement.

WuXi XDC Cayman Inc., through its subsidiary BioDlink International Company Limited, has launched voluntary conditional cash offers for all issued shares of TOT BIOPHARM International Co. Ltd. not already held by the offeror and its concert parties, as well as for the cancellation of all outstanding share options, and the parties intend to present these offers via a combined composite document that includes both the offer terms and the company’s board response. The dispatch of this composite document has been formally delayed beyond the standard 21‑day Takeovers Code deadline to on or before 13 February 2026, pending finalisation of independent financial advice and indebtedness disclosures, with regulators indicating they are minded to grant the necessary waiver, and shareholders and option holders are urged to await the document and exercise caution as completion of the transaction remains subject to conditions and may or may not proceed.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

More about TOT BIOPHARM International Co. Ltd.

TOT BIOPHARM International Co. Ltd. is a Hong Kong–listed biopharmaceutical company focused on the development, manufacturing and commercialization of oncology and other biologic drugs, while WuXi XDC Cayman Inc. and its affiliate BioDlink International Company Limited operate in the biologics and bioconjugate contract development and manufacturing space, with an emphasis on facilitating global biologic therapeutics development.

Average Trading Volume: 2,744,673

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.14B

For detailed information about 1875 stock, go to TipRanks’ Stock Analysis page.